Treatment Of Acute Deep Vein Thrombosis Of The Lower Ext

Clinical Center

Investigators

Linked publications & trials

Abstract

The objective of the study is to evaluate thrombolytic therapy using recombinant tissue plasminogen activator (rtPA) for treatment of acute deep vein thrombosis (DVT) of the lower extremity. While the conventional therapy, anticoagulation alone, is highly effective in prevention of life threatening pulmonary embolism, it does not preserve venous function in the affected leg, often leading to postphlebitic syndromes in subsequent years. The study is designed to evaluate efficacy, safety, and cost of this form of treatment for restoration of venous function in the lower extremity. Since start of the study, 17 patients have been treated. All except one patient had significant improvement. Five patients also had evidence of pulmonary embolism by lung scans prior to start of their treatment whereas only two patients have had evidence of small asymptomatic pulmonary emboli that developed during treatment, detected on ventilation perfusion lung scans that are obtained in all patients accepted into the protocol. None of these patients were clinically symptomatic. One patient developed a non-life-threatening biceps hematoma probably induced by automatic blood pressure monitoring during the rtPA treatment. No patients have required blood transfusions and no other complications have occurred. Over a followup period that ranges from 3 months to 5 years, none of our patients have developed either recurrent deep vein thrombosis or progression to postphlebitic syndromes.Pharmacokinetic studies in our patients have made major contributions to improving our understanding of thrombolytic therapy and toward development of safe, affordable, and effective regimens that will preserve the quality of life for victims of DVT.